肾癌患者生活质量的研究现状

外科研究与新技术 ›› 2015, Vol. 4 ›› Issue (1): 64-67.

肾癌患者生活质量的研究现状

荣海健¹,郑军华²

1. 同济大学附属第十人民医院
2. 同济大学附属第十人民医院泌尿外科

收稿日期:2015-04-02 修回日期:2015-04-09 出版日期:2015-03-28 发布日期:2015-04-01
通讯作者: 郑军华 E-mail:zhengjhO471@sina.com

Quality of Life in Patients with Renal Cell Carcinoma

Received:2015-04-02 Revised:2015-04-09 Online:2015-03-28 Published:2015-04-01

摘要/Abstract

摘要： [摘要] 肾细胞癌，简称肾癌，是泌尿系统最常见的恶性肿瘤之一。肾癌易复发或转移，对化疗、放疗和免疫治疗均不敏感，因此肾癌患者的生活质量和预后受到严重影响。近些年，对肾癌患者的生活质量研究关注显著增多，尤其是在生活质量评估的量表使用、手术切除的影响和靶向药物治疗的作用等方面。本文就肾癌患者生活质量的研究作一综述，为临床上肾癌的生活质量提高提供有力参考和研究依据。

关键词: [关键词] 肾癌, 生活质量, 转移性肾癌, 局限性肾癌, 靶向药物治疗

Abstract: [ABSTRACT] Renal cell carcinoma (RCC), is one of the most common malignant tumor in urological system. RCC with high recurrence rate and metastasis rate , is relatively resistant to radiation therapy and chemotherapy, which affects the quality of life(QoL) and prognosis of patients with RCC. In recent years, increasing attentions have been paid to the research of QoL, especially in available instruments to measure QoL, impact of surgical removal and targeted therapy. This review includes related researches and provides reference for clinical practice in RCC treatment.

Key words: [KEY WORDS] Renal cell carcinoma, Quality of life, Metastatic renal cell carcinoma, Localized renal cell carcinoma, Targeted therapy

荣海健郑军华. 肾癌患者生活质量的研究现状[J]. 外科研究与新技术, 2015, 4(1): 64-67.

参考文献

[1] Ferlay J, Shin H R, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer,2010,127(12):2893-2917.
[2] 叶定伟，张海梁. 中国肾癌诊治现状和发展趋势[J]. 中华泌尿外科杂志,2014,35(6):401-405.
[3] Demery M E, Thezenas S, Pouessel D, et al. Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function[J]. Anticancer Drugs,2012,23(2):143-148.
[4] 刘卫. 肾癌根治手术后患者生活质量的调查分析[D]. 大连医科大学,2013.
[5] Lambea J, Hinojo C, Lainez N, et al. Quality of life and supportive care for patients with metastatic renal cell carcinoma[J]. Cancer Metastasis Rev,2012,31 Suppl 1:S33-S39.
[6] Butt Z, Peipert J, Webster K, et al. General population norms for the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)[J]. Cancer,2013,119(2):429-437.
[7] Baum G, Basen-Engquist K, Swartz M C, et al. Comparing PROMIS computer-adaptive tests to the Brief Symptom Inventory in patients with prostate cancer[J]. Qual Life Res,2014,23(7):2031-2035.
[8] Salsman J M, Schalet B D, Andrykowski M A, et al. The impact of events scale: a comparison of frequency versus severity approaches to measuring cancer-specific distress[J]. Psychooncology,2015.
[9] Ames S C, Parker A S, Crook J E, et al. Quality of life of patients undergoing surgical treatment for newly-diagnosed, clinically localized renal cell carcinoma[J]. J Psychosoc Oncol,2011,29(6):593-605.
[10] 蒋鸿涛，王毅，秦国庆. 肾癌根治术后精神障碍临床分析[J]. 中外健康文摘,2011,08(46):467-468.
[11] 罗斌，王博，蒋学文. 影响肾癌预后的危险因素分析[J]. 中国实用医药,2011,06(11):36-37.
[12] Maclennan S, Imamura M, Lapitan M C, et al. Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer[J]. Eur Urol,2012,62(6):1097-1117.
[13] Clark P E, Schover L R, Uzzo R G, et al. Quality of life and psychological adaptation after surgical treatment for localized renal cell carcinoma: impact of the amount of remaining renal tissue[J]. Urology,2001,57(2):252-256.
[14] Xu K Y, Wu S. Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma[J]. Biomark Res,2015,3:5.
[15] Mitchell A P, Hirsch B R, Harrison M R, et al. Deferred Systemic Therapy in Patients With Metastatic Renal Cell Carcinoma[J]. Clin Genitourin Cancer,2014.
[16] Psutka S P, Kim S P, Gross C P, et al. The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization[J]. Urology,2015,85(2):442-450.
[17] Motzer R J, Hutson T E, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma[J]. J Clin Oncol,2009,27(22):3584-3590.
[18] 丁震宇. 舒尼替尼治疗肾细胞癌的新进展[J]. 临床肿瘤学杂志,2010,15(5):461-464.
[19] Rini B I, Choueiri T K, Elson P, et al. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma[J]. Cancer,2008,113(6):1309-1314.
[20] Bukowski R, Cella D, Gondek K, et al. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer[J]. Am J Clin Oncol,2007,30(3):220-227.
[21] Cella D. Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes[J]. Cancer Treat Rev,2009,35(8):733-737.
[22] 王青蓝. 索拉非尼靶向治疗晚期肾癌的临床价值分析[J]. 实用药物与临床,2013,16(4):288-290.
[23] Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma[J]. N Engl J Med,2007,356(22):2271-2281.
[24] 周爱萍，杜春霞，孙永琨，等. 替西罗莫司治疗转移性肾细胞癌初探[J]. 癌症进展,2012,10(3):301-305.
[25] Trask P C, Bushmakin A G, Cappelleri J C, et al. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib[J]. Acta Oncol,2008,47(5):843-851.
[26] 付桂英. 肾细胞癌治疗药--阿西替尼的研究进展[J]. 中国临床药理学杂志,2014(4):371-373.